Aptamer Group secures £270k in new orders and first cash licensing receiptsAptamer Group plc (LON:APTA), the developer of next-generation synthetic binders for the life sciences industry, has announced £190,000 of new fee-for-service orders and £80,000 of cash licensing receipts, demonstrating sustained commercial momentum and the commencement of high-margin, recurring revenues from its Optimer® platform. These new and extended contracts mean Aptamer now has multiple, ongoing Optimer® programmes with leading industry players, demonstrating sustained adoption of the platform and a growing, diversified fee-for-service revenue base. The Optimers generated under these agreements will support a range of research applications for the Group’s pharmaceutical partners, further embedding Optimer® binders within customers’ development pipelines. First cash licensing receipts from hot‑start PCR Optimer®Aptamer has received its first cash licensing receipts totalling £80,000 from a non-exclusive hot‑start PCR Optimer® licence signed in December 2025. The Group continues to progress additional Optimer® licensing opportunities across diagnostics, life‑science tools and therapeutics, building a portfolio of royalty-bearing assets alongside its established fee-for-service business.